Company Filing History:
Years Active: 2008-2021
Title: **Robert Siliciano: A Pioneer in Antiviral Research**
Introduction
Robert Siliciano, based in Baltimore, MD, is a distinguished inventor known for his significant contributions to the field of antiviral research. With a total of three patents to his name, Siliciano's work primarily focuses on combating HIV-1 replication through innovative therapeutic methods.
Latest Patents
Siliciano's latest patents reflect his dedication to advancing medical science. One notable invention is centered around antiviral proteins, where he discovered three proteins—BCL-G (BCL2L14), CMPK2, and LAMP3—that independently restrict HIV-1 replication both in vivo and in vitro. This patent outlines methods for administering an effective pharmaceutical composition comprising selected proteins to treat or prevent HIV infections.
Another important patent relates to methods for characterizing proviral reservoirs in nucleic acid samples. This invention provides methodologies to determine the proportion of intact, hypermutated, deleted, and/or defective proviruses, enhancing our understanding of HIV dynamics in human subjects.
Career Highlights
Robert Siliciano is affiliated with The Johns Hopkins University, where he continues his groundbreaking research. His innovative approaches in the laboratory have positioned him as a leader in the fight against HIV, offering hope for improved treatment strategies.
Collaborations
Throughout his career, Siliciano has collaborated with esteemed colleagues, including David Lee Thomas and Ashwin Balagopal. Together, they have contributed to significant advancements in antiviral therapies and the understanding of viral pathogenesis.
Conclusion
Robert Siliciano's inventive work is making lasting impacts in the fight against HIV. His patents not only reflect his commitment to scientific progress but also pave the way for future innovations in therapeutic approaches. As research in the antiviral field continues to evolve, Siliciano stands out as a pivotal figure in shaping the future of HIV treatment.